Galmed Pharmaceuticals Ltd GLMD.O:
GALMED ANNOUNCES TOP-LINE RESULTS IN ONCOLOGY MOA STUDIES: A 3-DRUG COMBINATION OF ARAMCHOL, STIVARGA® AND METFORMIN SIGNIFICANTLY ENHANCED GI TUMOR CELLS, KILLING IN-VIVO AND IN-VITRO
Source text: ID:nPn7wrlSha
Further company coverage: GLMD.O